SOVREMENNYE PODKhODY K PATOGENETIChESKOY TERAPII BOLEZNI AL'TsGEYMERA


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The main direction in the treatment of Alzheimer's disease (AD) is a replacement therapy aimed at overcoming neurotransmitter deficiency in different neuronal systems. Deficiency of acetylcholine is the basis of cognitive impairment and the subsequent development of total dementia. For the overcoming of cholinergic deficiency acetylcholinesterase inhibitors, such as rivastigmine, donepezil and galantamine, are widely used; their efficacy and safety in patients with AD were convincingly demonstrated in numerous domestic and foreign clinical trials. The number of glutamate receptors in the hippocampus is significantly reduced in AD., and the degree of reduction correlates with the severity of dementia. The basic glutamatergic strategy for the treatment of AD includes memantine, which has neuroprotective and positive symptomatic effects on the level of preserved glutamatergic synapses.

Texto integral

Acesso é fechado

Sobre autores

I. Kolykhalov

Email: ikolykhalov@yandex.ru

Bibliografia

  1. Alzheimer's Association, Alzheimer's Disease Facts and Figures, Alzheimer’s & Dementia 2012; 8(lssue 2): 67.
  2. Гаврилова С.И., Калын Я.Б. Социально-средовые факторы и состояние психического здоровья пожилого населения // Вестник Рос. АМН 2002; 9: 15-20.
  3. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 146: 939-44.
  4. Corey-Bloom J., Anand R., Veach J for the ENA-713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastig mine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65.
  5. Grossberg G., Irwin P., Spiegel R., et al. Rivastigmine in Alzheimer’s disease: efficacy over two years compared with historical controls. Poster presented at 10th Congress of the International Psychogcriatric Association (IPA). Nice, France, 9-14 September, 2001.
  6. Гаврилова С.И. Психические расстройства при первичных дегенеративных (атрофических) процессах головного мозга. Руководство по психиатрии / Под ред. А.С. Тиганова. М., 1999. С. 57-117.
  7. Колыхалов И.В., Селезнева Н.Д., Калын Я.Б.и др. Клиническая эффективность экселона при болезни Альцгеймера. В кн.: Болезнь Альцгеймера и старение: от нейробиологии к терапии. Материалы II Российской конференции / Под редакцией С.И. Гавриловой. М.,1999. С. 90-7.
  8. Potkin S.G., Anand R., Hartman R., Veach J. Impact of Alzheimer’s disease and rivastigmine treatment on activities of daily living over the couse of mild to moderately severe disease. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 713-20.
  9. Rogers S.L., Friedhoff L.T. and Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
  10. Rockwood K., Graham J., Fay S. Goal setting and attainment in patients with Alzheimer’s disease treated with donepezil. J Neurol Neurosurg Psychiatry 2002; 73: 500-7.
  11. Жариков Г.А., Калын Я.Б., Колыхалов И.В., Михайлова Н.М., Гаврилова С.И. Опыт применения арисепта (донепезила) в лечении болезни Альцгеймера. В кн. Болезнь Альцгеймера и старение. Материалы III Российской конференции / Под ред. С.И. Гавриловой. М., 2003. С. 76-87.
  12. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders 2000; 11: 11-8.
  13. Olin J., Schneider L. Galantamine for Alzheimer’s disease (Cochrane Review). Cochrane Library, issue 2. Oxford, 2001.
  14. Tariot P.N., Solomon P.R., Morris J.C., et al. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer’s Disease. Neurology 2000; 54: 2269-76.
  15. Wessel T., Gaens E. The long-term cognitive benefits of galantamine treatment in patients with Alzheimer’s disease (poster). 125th Annu Meet Am Neurol Assoc, Boston, October 2000.
  16. Wilcock G.K., Lilienfeld S., Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: A multicentre randomised controlled trial. BMJ 2000; 321: 1445-49.
  17. Davis K.L., Mohs R.C., Marin D., et al. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA 1999; 281: 1401-406.
  18. Feldman H., Sauter A., Donald A., et al. The Disability Assessment for Dementia scale: A 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 2001; 15: 89-95.
  19. Гаврилова С.И., Калын Я.Б., Колыхалов И.В. и др. Новые возможности холинергической терапии болезни Альцгеймера // Психиатрия 2005. № 2. С. 39-47.
  20. Hope T., Keene J., Fairburn C.G., et al. Natural history of behavioral changes and psychiatric symptoms in Alzheimer’s disease: A longitudinal study. Br J Psychiatry 1999; 174: 39-44.
  21. Tariot P.N., Solomon P.R., Morris JC., et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76.
  22. Monsch A.U., Heiter-Reiffenstuhl I., Braendle D. Galantamine reduces behavioural and psychological disturbances and related caregiver burden in Alzheimer’s disease patients. Poster at the 6th Congress of the European Federation of Neurological Societies, Vienna. 2002.
  23. Barak Y., Bodner E., Zemishlani H., et al. Donepezil for the treatment of behavioral disturbances in Alzheimer’s disease: a 6-month open trial. Arch Gerontol Geriatr 2001; 33: 237-41.
  24. Cummings J.L. Use of cholinesterase inhibitors in clinical practice: evidence based recommendations. Am J Geriatr Psychiatry 2003; 11 (2): 131 -45.
  25. Bullock R., Moulias R., Steinwachs K.C., et al. Effects of rivastigmine on behavioral symptoms in nursing home patients with Alzheimer’s disease. International Psychogeriatrics 2001; 13(2): 242.
  26. Cummings J.L., Anand R., Koumaras B., et al. Rivastigmine provides behavioral benefits to Alzheimer’s disease patients residing in a nursing home: findings from a 26 week trial. Neurology 2000; 54(3): 468-69.
  27. Колыхалов И.В., Рассадина Г.А. Сравнительная оценка эффективности ингибиторов ацетилхолинэстеразы в лечении поведенческих и психотических расстройств у больных деменцией в условиях стационара // Психиатрия 2009. № 1. С. 51-6.
  28. Ruther E., Glaser A., Bleich S., et al. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatry 2000; 33: 103-8.
  29. Ricke J., Glaser A. Wirksamkeit und Vertraglichkeit von Memantine bei Patienten mit dementiellem Syndrom. Med Welt 1996; 47: 251-54.
  30. Гаврилова С.И., Калын Я.Б., Селезнева Н.Д. и др. Глутаматергическая терапия болезни Альцгеймера на стадии умереннотяжелой и тяжелой деменции: результаты 26-недельного исследования эффективности и безопасности препарата акатинол мемантин // Журнал невропатологии и психиатрии им С.С. Корсакова 2005. № 2. С. 72-6.
  31. Колыхалов И.В., Гаврилова С.И., Калын Я.Б. и др. Сравнительное клиническое исследование безопасности и пере-носимости одноразового приема препарата акатинол мемантин в сравнении с двухразовым приемом у пациентов с умеренно выраженной и умеренно тяжелой деменцией при болезни Альцгеймера // Журнал невропатологии и психиатрии им С.С. Корсакова 2012. № 1. С. 35-9.
  32. Gautheir S., Wirth Y., Mobius H.J. Effects of Memantine in Behavioural Symptoms in Alzheimer’s Disease Patients: An Analysis of the Neuropsychiatric Inventory (NPI) Data of Two Randomized, Controlled Studies. Int J Geriatr Psychiatry 2005; 20: 1-6.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2012